160 related articles for article (PubMed ID: 3907279)
21. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
22. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
23. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
24. [New chemotherapy approaches to psychoses].
Olié JP; Baylé FJ
Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
[TBL] [Abstract][Full Text] [Related]
25. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
26. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic implications of different oil vehicles used in depot neuroleptic treatment.
Knudsen P; Hansen LB; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():7-10. PubMed ID: 3865501
[TBL] [Abstract][Full Text] [Related]
28. [Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
Lesch OM; Dietzel-Rogan M; Musalek M; Rajna P; Rustembegovich A; Schjerve M; Walter H
Psychiatr Prax; 1985 Mar; 12(2):63-8. PubMed ID: 3887443
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
31. [Perphenazine enanthate. Results of a 1-year open multicenter study].
Baruch P; Brion S; Broussolle P; Gayral LF; Ropert R; Volmat R; Porot M
Encephale; 1989; 15(5):449-55. PubMed ID: 2686965
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of effectiveness and tolerance of the long-term treatment with bromoperidol decanoate in psychotic disorders].
Levi Minzi A; Laviani M
Minerva Psichiatr; 1992; 33(1):51-5. PubMed ID: 1406161
[TBL] [Abstract][Full Text] [Related]
33. [Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
Svestka J; Rysánek R; Náhunek K; Cesková E
Cesk Psychiatr; 1990 Jun; 86(3):145-56. PubMed ID: 2225184
[TBL] [Abstract][Full Text] [Related]
34. Large variations of plasma levels during maintenance treatment with depot neuroleptics.
Tuninger E; Levander S
Br J Psychiatry; 1996 Nov; 169(5):618-21. PubMed ID: 8932892
[TBL] [Abstract][Full Text] [Related]
35. [Effects and side effects of depot neuroleptics as perceived by patients].
Trenckmann U
Psychiatr Prax; 1990 Sep; 17(5):184-7. PubMed ID: 1980015
[TBL] [Abstract][Full Text] [Related]
36. [Results of long-term treatment with depot neuroleptics in schizophrenic patients].
Klein A; Ehle G
Psychiatr Neurol Med Psychol (Leipz); 1988 Mar; 40(3):159-67. PubMed ID: 3132729
[TBL] [Abstract][Full Text] [Related]
37. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.
Anand R; Geffen Y; Vasile D; Dan I
Clin Neuropharmacol; 2010; 33(6):297-302. PubMed ID: 20921890
[TBL] [Abstract][Full Text] [Related]
38. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial.
Ahlfors UG; Dencker SJ; Gravem A; Remvig J
Acta Psychiatr Scand Suppl; 1980; 279():77-91. PubMed ID: 6996426
[TBL] [Abstract][Full Text] [Related]
39. [A comparative study of the longacting neuroleptics perphenazin-enanthate and fluspirilene (author's transl)].
Tegeler J; Floru L
Pharmakopsychiatr Neuropsychopharmakol; 1979 Sep; 12(5):357-65. PubMed ID: 504342
[TBL] [Abstract][Full Text] [Related]
40. [Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazinedecanoate, fluspirilene, penfluridol, perphenazine-enanthate and pipothiazinepalmitate].
Angst J; Woggon B
Arzneimittelforschung; 1975 Feb; 25(2):267-70. PubMed ID: 1091272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
